AP646A - Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. - Google Patents

Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. Download PDF

Info

Publication number
AP646A
AP646A APAP/P/1997/001092A AP9701092A AP646A AP 646 A AP646 A AP 646A AP 9701092 A AP9701092 A AP 9701092A AP 646 A AP646 A AP 646A
Authority
AP
ARIPO
Prior art keywords
fumagillol
preparation
fumagillin
drugs
ester
Prior art date
Application number
APAP/P/1997/001092A
Other languages
English (en)
Other versions
AP9701092A0 (en
Inventor
Jean-Michel Molina
Francis Deriyubm
Original Assignee
Sanofi Synthelabo
Hopitaux Paris Assist Publique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo, Hopitaux Paris Assist Publique filed Critical Sanofi Synthelabo
Publication of AP9701092A0 publication Critical patent/AP9701092A0/xx
Application granted granted Critical
Publication of AP646A publication Critical patent/AP646A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1997/001092A 1995-03-27 1996-03-26 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. AP646A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27
PCT/FR1996/000448 WO1996030010A2 (fr) 1995-03-27 1996-03-26 Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales

Publications (2)

Publication Number Publication Date
AP9701092A0 AP9701092A0 (en) 1997-10-31
AP646A true AP646A (en) 1998-04-27

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001092A AP646A (en) 1995-03-27 1996-03-26 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.

Country Status (25)

Country Link
US (1) US5900431A (enrdf_load_stackoverflow)
EP (1) EP0817626B1 (enrdf_load_stackoverflow)
JP (1) JP3260378B2 (enrdf_load_stackoverflow)
KR (1) KR100286920B1 (enrdf_load_stackoverflow)
CN (1) CN1072485C (enrdf_load_stackoverflow)
AP (1) AP646A (enrdf_load_stackoverflow)
AT (1) ATE172641T1 (enrdf_load_stackoverflow)
AU (1) AU706161B2 (enrdf_load_stackoverflow)
CA (1) CA2216623C (enrdf_load_stackoverflow)
CZ (1) CZ286821B6 (enrdf_load_stackoverflow)
DE (1) DE69600879T2 (enrdf_load_stackoverflow)
DK (1) DK0817626T3 (enrdf_load_stackoverflow)
EA (1) EA000150B1 (enrdf_load_stackoverflow)
ES (1) ES2128846T3 (enrdf_load_stackoverflow)
FR (1) FR06C0014I2 (enrdf_load_stackoverflow)
HU (1) HU224028B1 (enrdf_load_stackoverflow)
IS (1) IS2048B (enrdf_load_stackoverflow)
NO (1) NO315968B1 (enrdf_load_stackoverflow)
NZ (1) NZ304906A (enrdf_load_stackoverflow)
OA (1) OA10515A (enrdf_load_stackoverflow)
PL (1) PL183378B1 (enrdf_load_stackoverflow)
SK (1) SK283883B6 (enrdf_load_stackoverflow)
TR (1) TR199701048T1 (enrdf_load_stackoverflow)
UA (1) UA41446C2 (enrdf_load_stackoverflow)
WO (1) WO1996030010A2 (enrdf_load_stackoverflow)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE172641T1 (de) * 1995-03-27 1998-11-15 Sanofi Sa Verwendung von fumagillol und seinen derivaten zur herstellung von arzneimitteln gegen darminfektionen
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
ATE361757T1 (de) * 1999-02-26 2007-06-15 Sanofi Aventis Stabile fumagillin-formulierung
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
CN101990441A (zh) * 2007-11-28 2011-03-23 默萨那治疗学股份有限公司 生物相容的生物可降解的烟曲霉素类似物轭合物
WO2010009374A1 (en) * 2008-07-18 2010-01-21 Zafgen, Inc. Methods of treating an overweight or obese subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
WO2011044506A2 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
JP5827239B2 (ja) 2010-01-08 2015-12-02 ザフゲン,インコーポレイテッド フマギロール型化合物並びにその製造方法及び使用方法
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
MX2013000836A (es) 2010-07-22 2013-09-26 Zafgen Inc Compuestos triciclicos y metodos para elaborar y usar los mismos.
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
JP2013543899A (ja) 2010-11-29 2013-12-09 ザフゲン,インコーポレイテッド 6−o−(4−ジメチルアミノエトキシ)シンナモイルフマギロールの非連日投与を用いた肥満の治療
EP2668169B1 (en) 2011-01-26 2017-11-15 Zafgen, Inc. Tetrazole compounds and methods of making and using same
MX342257B (es) 2011-03-08 2016-09-21 Zafgen Inc Derivados y análogos de oxaspiro [2.5] octano.
EP2705030B1 (en) 2011-05-06 2016-07-27 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
AU2012253760B2 (en) 2011-05-06 2016-02-04 Zafgen, Inc. Tricyclic pyrazole sulfonamide compounds and methods of making and using same
MX343687B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
JP6035347B2 (ja) 2012-01-18 2016-11-30 ザフゲン,インコーポレイテッド 三環式スルホンアミド化合物ならびにその作製および使用方法
CA2861381A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
KR20150016303A (ko) 2012-05-07 2015-02-11 자프겐 인크. 6-o-(4-디메틸아미노에톡시) 신나모일 푸마지롤의 옥살레이트 염의 다형체 염 및 이의 제조 및 사용 방법
CN104363905A (zh) 2012-05-08 2015-02-18 扎夫根股份有限公司 用metap2抑制剂治疗下丘脑性肥胖
JP6177888B2 (ja) 2012-05-09 2017-08-09 ザフゲン,インコーポレイテッド フマギロール型化合物ならびにその製造および使用方法
WO2014071369A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
EP2917197B1 (en) 2012-11-05 2019-06-05 Zafgen, Inc. Tricyclic compounds and methods of making and using same
EP2916833A1 (en) 2012-11-05 2015-09-16 Zafgen, Inc. Methods of treating liver diseases
BR112015023390A2 (pt) 2013-03-14 2017-07-18 Zafgen Inc métodos para tratar de doença renal e outros distúrbios
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019946A1 (en) * 1993-03-01 1994-09-15 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
JPH06504262A (ja) * 1990-07-27 1994-05-19 レブリゲン コーポレーション 脈管形成性の病気の処置用の新規な方法と組成物
ATE172641T1 (de) * 1995-03-27 1998-11-15 Sanofi Sa Verwendung von fumagillol und seinen derivaten zur herstellung von arzneimitteln gegen darminfektionen
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
WO1998005293A2 (en) * 1996-08-02 1998-02-12 The Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019946A1 (en) * 1993-03-01 1994-09-15 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin

Also Published As

Publication number Publication date
IS2048B (is) 2005-09-15
SK130797A3 (en) 1998-03-04
WO1996030010A2 (fr) 1996-10-03
EP0817626A2 (fr) 1998-01-14
ES2128846T3 (es) 1999-05-16
ATE172641T1 (de) 1998-11-15
HUP9801220A3 (en) 2001-10-29
DK0817626T3 (da) 1999-07-12
AU706161B2 (en) 1999-06-10
PL183378B1 (pl) 2002-06-28
NO974466D0 (no) 1997-09-26
PL322470A1 (en) 1998-02-02
EP0817626B1 (fr) 1998-10-28
JP3260378B2 (ja) 2002-02-25
WO1996030010A3 (fr) 1996-11-28
CN1179715A (zh) 1998-04-22
US5900431A (en) 1999-05-04
KR100286920B1 (ko) 2001-04-16
NO315968B1 (no) 2003-11-24
MX9707150A (es) 1998-07-31
DE69600879T2 (de) 1999-06-02
DE69600879D1 (de) 1998-12-03
FR06C0014I1 (enrdf_load_stackoverflow) 2006-11-17
CZ304997A3 (en) 1997-12-17
UA41446C2 (uk) 2001-09-17
CA2216623C (en) 2005-05-31
TR199701048T1 (xx) 1998-01-21
JPH11506421A (ja) 1999-06-08
NO974466L (no) 1997-09-26
CZ286821B6 (en) 2000-07-12
OA10515A (fr) 2002-04-24
FR06C0014I2 (enrdf_load_stackoverflow) 2006-12-29
HU224028B1 (hu) 2005-05-30
SK283883B6 (sk) 2004-04-06
HUP9801220A2 (hu) 1999-09-28
EA199700267A1 (ru) 1998-04-30
NZ304906A (en) 1999-06-29
IS4557A (is) 1997-09-11
AP9701092A0 (en) 1997-10-31
EA000150B1 (ru) 1998-10-29
AU5278696A (en) 1996-10-16
KR19980703271A (ko) 1998-10-15
CN1072485C (zh) 2001-10-10
CA2216623A1 (en) 1996-10-03

Similar Documents

Publication Publication Date Title
AP646A (en) Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.
US4101647A (en) Oral dosage form for X-ray contrast media containing a pharmaceutically acceptable base and method of use thereof
AU608853B2 (en) Inhibitors of glycoprotein processing having anti- retroviral activity
JPH0232093A (ja) 抗レトロウィルスジフルオロ化ヌクレオシド類
EP0190851B1 (en) Improved antiinflammatory composition
JPH0610141B2 (ja) エイズウイルス性疾患処置剤
US4895851A (en) Use of oxoquinazoline derivatives in the treatment of hyperuricaemia
MXPA97007150A (en) Use of fumagilol and its derivatives to prepare medicines intended to combat intestine infections
US6593329B1 (en) Method for the treatment or prevention of coronary graft vasospasm
US20230144875A1 (en) Highly purified eicosapentaenoic acid, as free fatty acid for treatment of coronaviruses and specifically novel coronavirus-19 (covid-19)
KR20010072640A (ko) 폐고혈압 치료방법
EP0555302A1 (en) Method of treating demyelinating disease
Kutscher et al. Amphotericin B in the treatment of oral monilial infections
US7485642B2 (en) Method for treating septic shock
EP0402477B1 (en) Use of isocarbacyclins for preventing or treating organ diseases
Stratigos et al. Treatment of gonorrhoea with spectinomycin hydrochloride
JPH0132804B2 (enrdf_load_stackoverflow)
JPH04266822A (ja) システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
EP0118968A1 (en) Use of avilamycin to control swine dysentery
JPS58210010A (ja) 抗腫瘍剤
JPH02174721A (ja) 脂質低下剤
JPH02275822A (ja) 語音聴力改善剤
JPH0899883A (ja) 膵炎治療剤